Healthcare Industry News: GSK
News Release - August 11, 2016
PrEP Biopharm Limited announces new CFO, Mike McGuinness, and new Head of CMC, Anna SlaterLONDON, Aug. 11, 2016 -- (Healthcare Sales & Marketing Network) -- PrEP Biopharm Limited, a private independent drug development company for respiratory infectious disease products, announced today that effective immediately Mike McGuinness has joined the company as Chief Financial Officer and Anna Slater has joined as Head of Chemistry, Manufacturing and Controls.
Mike McGuinness is a CPA with more than 30 years in financial and operational leadership roles. Most recently, he was the Co-founder and COO of Proception Medical, a medical device startup. Previously he has served as the CFO of Nextremity Solutions, Inc., a private medical device company, Manhattan Pharmaceuticals, Inc., a publicly traded pharmaceutical company, Vyteris, Inc., a publicly traded drug delivery company and Epigenesis Pharmaceuticals, Inc., a privately held biotech. During the course of his career, Mike has closed $500 million in financing and licensing deals, led an IPO and two mergers and sat on the Board of four other companies.
Anna Slater has 30 years of industry experience in pharmaceutical development, scale-up, manufacturing, regulatory filing and launch across a broad range of dosage forms, delivery devices and therapeutic areas. She joins PrEP Biopharm from GlaxoSmithKline where she spent 28 years in a wide range of CMC capacities. Most recently she was the Global Head of Analytical Technologies and CMC lead for ARNUITY™ ELLIPTA™ and VI Monotherapy. Prior to that she was a Senior Director in the global Inhaled Product & Device Technology Leadership Team, with accountability for CMC development of drug products and delivery devices for the GSK intranasal and allergy portfolio (Candidate Selection to Launch) and managing a department responsible for aqueous respiratory products and the RELENZA™ ROTACAP™ Pandemic Response.
"I'm incredibly excited to have Mike and Anna join the PrEP Leadership Team," said Ryan Muldoon, CEO of PrEP Biopharm. "They each have a tremendous track record of success in efficiently bringing new drugs to market. Their experience and insights will have an immediate impact as we move PrEP-001 through Phase 2 and plan for future development."
"I can't imagine a more exciting time to join PrEP Biopharm," said Mr. McGuinness. "The unmet medical need in the cold and flu market is enormous and I look forward to working with the PrEP Biopharm team to try and address it in a very meaningful way."
"Most of my career has focused on the strategic and technical CMC aspects of drug development for respiratory diseases" said Ms. Slater. "I hope my experience will help accelerate the development of PrEP-001 and I'm really pleased to be joining the team at a very dynamic time for PrEP Biopharm."
About PrEP Biopharm Limited:
Prep Biopharm Limited is an independent, development stage biopharmaceutical company focused on the prevention of respiratory infections. The privately held company's flagship product, PrEP-001, is in phase 2 for the prevention of upper respiratory tract viral infections.
Source: PrEP Biopharm
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.